AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
Markets

Wall Street closes higher, Nasdaq sets record as potential vaccines show promise

  • Amazon.com Inc and Microsoft Corp provided the biggest boosts to the Nasdaq and the S&P500, but industrials retreated, capping the Dow's gains.
  • "In the next few weeks there will start to be risk assessments made on how the size of the next round of financial stimulus," Sroka added.
Published July 21, 2020

NEW YORK: Wall Street gained ground on Monday and surging technology shares pushed the Nasdaq to a record closing high, as promising trial results from potential COVID-19 vaccines helped investors look beyond spiraling new cases of the disease.

Amazon.com Inc and Microsoft Corp provided the biggest boosts to the Nasdaq and the S&P500, but industrials retreated, capping the Dow's gains.

Deaths in the United States from COVID-19 passed the 140,000 mark over the weekend, as cases continued to rise in 42 of 50 states.

Trials of potential vaccines have shown promise. Most recently, drugs from AstraZenica, CanSino Biologics Inc and from a partnership between Pfizer Inc and German biotech firm BioNTech were safely administered and induced immune responses.

"Developments on COVID, positive or negative, have become the new risk-on/risk-off binary trigger for the market," said Joseph Sroka, chief investment officer at NovaPoint in Atlanta. "A year ago it was trade."

"In the next few weeks there will start to be risk assessments made on how the size of the next round of financial stimulus," Sroka added.

The US Congress, still looking to mitigate the pandemic's economic effects, was set for a week of partisan wrangling over a new relief package, with two weeks until enhanced jobless benefits expire for millions of Americans.

Unofficially, the Dow Jones Industrial Average rose 8.98 points, or 0.03%, to 26,680.93, the S&P 500 gained 27.11 points, or 0.84%, to 3,251.84 and the Nasdaq Composite added 263.90 points, or 2.51%, to 10,767.09.

Of the 11 major sectors in the S&P 500, consumer discretionary and tech enjoyed the largest percentage gains.

Second-quarter earnings season chugged along. Some 48 companies in the S&P 500 have posted results, with 77.1% of those beating consensus, according to Refinitiv data.

In aggregate, analysts now expect S&P 500 second-quarter earnings to have dropped 43.2% year-on-year, per Refinitiv.

This week, Microsoft Corp, Amazon.com Inc, Tesla Inc and Intel Corp are among the high-profile companies expected to report quarterly results.

Shares Halliburton Co rose after posting a surprise adjusted quarterly profit and better-than-expected cash flow due to cost-cutting.

Noble Energy Inc jumped on news that Chevron Corp agreed to buy the oil and gas producer for $5 billion.

Chevron ended the session lower.

Moderna Inc plunged on positive results from its competitors' rival COVID-19 drug trials.

Comments

Comments are closed.